Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramiracetam SCHEMBL121209 | 0.99 | LMNA (0.47) | LMNAHTTTSHRKMT2AADRA1D | |
| Pramiracetam SCHEMBL11556360 | 0.99 | LMNA (0.47) | LMNAHTTTSHRKMT2AADRA1D | |
| Pramiracetam SCHEMBL1171471 | 0.97 | LMNA (0.46) | LMNAHTTTSHRKMT2AADRA1D | |
| Pramiracetam SCHEMBL120423 | 0.96 | LMNA (0.46) | LMNAHTTTSHRKMT2AADRA1D | |
| Pramiracetam SCHEMBL4431064 | 0.89 | LMNA (0.40) | LMNAHTTTSHRKMT2AADRA1D | |
| Pramiracetam SCHEMBL2136275 | 0.87 | LMNA (0.57) | LMNAHTTTSHRKMT2AADRA1D | |
| SCHEMBL8961554 | 0.85 | LMNA (0.45) | LMNAHTTTSHRKMT2AADRA1D | |
| SCHEMBL11553497 | 0.85 | HTT (0.50) | LMNAHTTTSHRKMT2AADRA1D | |
| SCHEMBL11554851 | 0.84 | TP53 (0.51) | LMNAHTTTSHRKMT2AADRA1D | |
| Hydrochloric Acid SCHEMBL11555232 | 0.83 | HTT (0.49) | LMNAHTTTSHRKMT2AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4291237-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | Phoenix Nest Inc. (US) | 2023-12-20 | — | — | EP | claimed |
| WO-2023164338-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS | THE JONATHAN HURT LIVING TRUST (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230157976-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | THERMOLIFE INTERNATIONAL, LLC | 2023-05-25 | — | — | US | claimed |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | UNIV CALIFORNIA (US) | 2023-03-30 | — | — | US | claimed |
| US-4910023-A | Containing silica | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | claimed |
| EP-0345787-A2 | Drug in combination with flavor masking agent and method for making same | WARNER-LAMBERT COMPANY (US) | 1989-12-13 | — | — | EP | claimed |
| US-4876260-A | NERVOUS SYSTEM DISORDERS | STATE OF ISRAEL, ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IL) | 1989-10-24 | — | — | US | claimed |
| US-4855290-A | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1989-08-08 | — | — | US | claimed |
| EP-0314444-A2 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-05-03 | — | — | EP | claimed |
| EP-0303391-A2 | Optical isomers of a spiroquinuclidine derivative | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-02-15 | — | — | EP | claimed |
| EP-0243336-A1 | Pharmaceutical compositions for the treatment of intermittent claudication | U C B, S.A. (BE) | 1987-10-28 | — | — | EP | claimed |
| EP-0205247-A2 | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1986-12-17 | — | — | EP | claimed |
| EP-0116238-A1 | Therapeutic compositions and their use in enhancing brain function | BIOMEASURE, INC. (US) | 1984-08-22 | — | — | EP | claimed |
| US-4145347-A | TREATMENT OF SENILITY, AMNESIA AND LEARNING DISORDERS | PARKE, DAVIS & COMPANY (US) | 1979-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | CHRNA7, CHRNA3, CHRNA6 | LMNA 3147/4885HTT 450/4885TSHR 1911/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | LMNA 2131/4885HTT 500/4885TSHR 1743/4885 |
| US-20230157976-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | SLC6A2, CPT1B, GYS1 | LMNA 4797/4885HTT 38/4885TSHR 1650/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | LMNA 4093/4885HTT 789/4885TSHR 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.